Ipilimumab

Ipilimumab Reactions 1704, p208 - 2 Jun 2018 Transaminitis: case report A 69-year-old man developed transaminitis during treatment with ipilimumab [route and dosage not stated]. The man, who had a V600E BRAF-mutated metastatic melanoma, started receiving treatment with trametinib, ipilimumab and dabrafenib. Despite the treatment, he had disease progression. He then received treatment with pembrolizumab and glembatumumab vedotin. In June 2016, he started receiving ipilimumab and nivolumab. However, he developed transaminitis, which was attributed to ipilimumab. Thereafter, his therapy was continued with nivolumab without any complication [duration of treatment to reaction onset and outcome not stated]. Author comment: "At this time in June 2016, the patient was started on ipilimumab and nivolumab. After experiencing transaminitis, he was continued on nivolumab alone, which he tolerated well." Schwager Z, et al. Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy. JAAD Case Reports 4: 421-423, No. 5, Jun 2018. Available from: URL: http://doi.org/10.1016/j.jdcr.2017.10.019 - USA 803323583 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ipilimumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/ipilimumab-Vkx0w0ThYa
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46851-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p208 - 2 Jun 2018 Transaminitis: case report A 69-year-old man developed transaminitis during treatment with ipilimumab [route and dosage not stated]. The man, who had a V600E BRAF-mutated metastatic melanoma, started receiving treatment with trametinib, ipilimumab and dabrafenib. Despite the treatment, he had disease progression. He then received treatment with pembrolizumab and glembatumumab vedotin. In June 2016, he started receiving ipilimumab and nivolumab. However, he developed transaminitis, which was attributed to ipilimumab. Thereafter, his therapy was continued with nivolumab without any complication [duration of treatment to reaction onset and outcome not stated]. Author comment: "At this time in June 2016, the patient was started on ipilimumab and nivolumab. After experiencing transaminitis, he was continued on nivolumab alone, which he tolerated well." Schwager Z, et al. Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy. JAAD Case Reports 4: 421-423, No. 5, Jun 2018. Available from: URL: http://doi.org/10.1016/j.jdcr.2017.10.019 - USA 803323583 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off